Navigation Links
Adamis Pharmaceuticals CEO Provides Update for Shareholders

ur Beclomethasone-HFA product to initiate Phase III studies in asthma and COPD
  • Finalizing our allergic rhinitis product development in order to initiate Phase III clinical trials
  • Acquiring or in-licensing an established product or technology that, following regulatory marketing approvals, will compete in large (multi-billion dollar) product markets and will be synergistic with our existing assets.
  • On the Biotech side, we are focused on:

    • Completing our Phase I prostate cancer drug trial
    • Finalizing the activities necessary to begin a Phase I/II trial for our second prostate compound
    • Initiating a Phase II prostate cancer vaccine trial for TeloB-VAX.

    If we are able to complete additional financing transactions and make progress on our objectives, we intend to take the necessary steps to be in a position to list our common stock on a national stock exchange such as the NYSE-Amex or NASDAQ.  An up-listing could lead to an increase in shareholder value, give Adamis more market exposure, increase liquidity and partnering activities and increase our shareholder base to include more fundamental health care investors.

    I would like to thank all of our shareholders for their continued support and patience.  We will all do our very best to make Adamis a company that you will all be very proud of owning.

    Best regards,

    Dennis J. Carlo , Ph.D
    President and CEO

    About Adamis Pharmaceuticals Corporation

    Adamis Pharmaceuticals Corporation is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology.  Products in its specialty pharmaceutical pipeline include the Epinephrine Injection PFS syringe for use in the emergency treatment of a

    SOURCE Adamis Pharmaceuticals Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    2. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    3. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    4. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    5. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    6. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    7. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    8. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    9. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    10. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
    11. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
    Post Your Comments:
    (Date:4/27/2015)... Ohio (PRWEB) April 27, 2015 ... of an agreement with Joslin Diabetes Center (“Joslin”) ... 2b study of Diasome’s novel Hepatocyte Directed Vesicle ... Type 1 diabetes. , Located in Boston, ... clinical care and education organization dedicated to the ...
    (Date:4/24/2015)... and Tempe, AZ (PRWEB) April 24, 2015 ... and Arizona State University (ASU) have entered into an ... projects. , A memorandum of agreement signed by the ... distance learning, student success and other services particularly, though ... , “We have complementary strengths and a similar ...
    (Date:4/24/2015)... MONTREAL , April 24, 2015 /CNW Telbec/ - Mirego, ... part of the making of three mobile app extensions for ... for its clients, Familiprix, OMSignal and MediaMiser, these ... information thanks to functions designed specifically for wrist use.  ... the Apple Watch is a highly customizable tactile smartwatch that ...
    (Date:4/23/2015)... CA (PRWEB) April 23, 2015 Athena ... personal development of executive women in San Diego’s technology ... the 17th Annual Pinnacle Awards at their Gala on ... Hyatt Hotel. Register now at , ... support the Athena San Diego vision of fostering networking, ...
    Breaking Biology Technology:Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
    ... 5 Dynamic Alert,Limited (OTC Bulletin Board: DYMC) ... its target markets for its pharmaceutical product line-up. ... for enhancing rapid onset,through oromucosal absorption, topical applications, ... internal use. Some products will have,specific uses, while ...
    ... Dec. 5 Early clinical experience with the FDA,cleared ... of ultrasound guided cryoablation to completely eradicate,small, unifocal Invasive ... study was presented at the 94th Scientific Assembly and ... November 29 -,December 5, 2008. , ...
    ... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext ... Agreement with the ("Harris Moran") has ... recently announced corporate restructuring. , ... parent company, Limagrain, restructured its vegetable seed operations and ...
    Cached Biology Technology:Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 2Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 3Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3
    (Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
    (Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
    (Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
    Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
    ... of Pennsylvania School of Medicine & School of Engineering ... deliver drugs to tumors. By using a cylindrical-shaped carrier ... paclitaxel to an animal model of lung cancer ten ... findings have implications for drug delivery as well as ...
    ... vitamin was named, what is known about them ... public health, says Irwin Rosenberg, MD, University Professor, ... at the Jean Mayer USDA Human Nutrition Research ... on his presentation at the National Institutes of ...
    ... was published in an advance online edition of the Proceedings ... April 9, 2007. , The study provides new evidence that ... is activated by the protein SGT1, which also activates Resistance ... pathogens. The study also confirms structural similarities between the Nod1 ...
    Cached Biology News:Penn researchers show how nanocylinders deliver medicine better than nanospheres 2Vitamins: Science doesn't always match policy 2Scripps research study shows humans and plants share common regulatory pathway 2Scripps research study shows humans and plants share common regulatory pathway 3
    ... service is for when you need to make ... their transformation efficiency. Our services for preparing competent ... applications. MCLab's custom competent cell service offers: ... Fast turnaround Quality control ...
    ... WR Cryoscope for molecular weight determinations for petroleum-based applications. Multiple solvents can be used, such ... ... ... ...
    Growth Medium / Media...
    ... Sensitivity Laboratory Osmometer for 50 L samples. Operating head automatically rises at the end of determination; triple-point ... ... ... ...
    Biology Products: